AstraZeneca

News

EU regulators approve AstraZeneca's Lynparza in pancreatic c...

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) in pancreatic cancer patients with a certain mutation.

News

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with alternatives from Roche and A

News

GSK's kidney disease anaemia drug approved in Japan, taking ...

GlaxoSmithKline’s drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas.

News

Merck KGaA's ATR cancer drug cleared for further trials afte...

Merck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in a phase 1 study.

News

Pills spilling out of a prescription bottle on 100 dollar paper currency

After Celgene deal, BMS shoots up pharma market cap rankings

Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, according to a new analysis by GlobalDat

News

Coronavirus vaccine: how pharma is picking up the pace

AZ promises to deliver 400m doses of COVID-19 vaccine to Eur...

AstraZeneca has followed through on its pledge to provide its COVID-19 vaccine at cost during the pandemic, saying it has agreed to supply 400m doses to the European Inclusive

EU regulators approve AstraZeneca's Lynparza in pancreatic c...

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

GSK's kidney disease anaemia drug approved in Japan, taking ...

Merck KGaA's ATR cancer drug cleared for further trials afte...

After Celgene deal, BMS shoots up pharma market cap rankings

AZ promises to deliver 400m doses of COVID-19 vaccine to Eur...

AbbVie tries a new approach in 340B programme battle

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks